Format
Sort by

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 25

1.

HLA Allele Frequencies in 5802 Koreans: Varied Allele Types Associated with SJS/TEN According to Culprit Drugs.

Park HJ, Kim YJ, Kim DH, Kim J, Park KH, Park JW, Lee JH.

Yonsei Med J. 2016 Jan;57(1):118-26. doi: 10.3349/ymj.2016.57.1.118.

2.

Stevens-Johnson syndrome and toxic epidermal necrolysis: an update on pharmacogenetics studies in drug-induced severe skin reaction.

Rufini S, Ciccacci C, Politi C, Giardina E, Novelli G, Borgiani P.

Pharmacogenomics. 2015 Nov;16(17):1989-2002. doi: 10.2217/pgs.15.128. Epub 2015 Nov 10.

PMID:
26555663
3.

Allopurinol hypersensitivity: investigating the cause and minimizing the risk.

Stamp LK, Day RO, Yun J.

Nat Rev Rheumatol. 2016 Apr;12(4):235-42. doi: 10.1038/nrrheum.2015.132. Epub 2015 Sep 29. Review. Erratum in: Nat Rev Rheumatol. 2016 Apr;12(4):i.

PMID:
26416594
4.

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update.

Saito Y, Stamp LK, Caudle KE, Hershfield MS, McDonagh EM, Callaghan JT, Tassaneeyakul W, Mushiroda T, Kamatani N, Goldspiel BR, Phillips EJ, Klein TE, Lee MT; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2016 Jan;99(1):36-7. doi: 10.1002/cpt.161. Epub 2015 Jul 16.

PMID:
26094938
5.

Genetic markers associated with cutaneous adverse drug reactions to allopurinol: a systematic review.

Jarjour S, Barrette M, Normand V, Rouleau JL, Dubé MP, de Denus S.

Pharmacogenomics. 2015;16(7):755-67. doi: 10.2217/pgs.15.21. Epub 2015 May 12. Review.

PMID:
25965122
6.

Immunologic basis for allopurinol-induced severe cutaneous adverse reactions: HLA-B*58:01-restricted activation of drug-specific T cells and molecular interaction.

Lin CH, Chen JK, Ko TM, Wei CY, Wu JY, Chung WH, Chen SY, Liao YD, Hung SI, Chen YT.

J Allergy Clin Immunol. 2015 Apr;135(4):1063-5.e5. doi: 10.1016/j.jaci.2014.09.041. Epub 2014 Nov 11. No abstract available.

PMID:
25458913
7.

T cell-mediated hypersensitivity reactions to drugs.

Pavlos R, Mallal S, Ostrov D, Buus S, Metushi I, Peters B, Phillips E.

Annu Rev Med. 2015;66:439-54. doi: 10.1146/annurev-med-050913-022745. Epub 2014 Oct 27. Review.

8.

Detection of HLA-B*58:01 with TaqMan assay and its association with allopurinol-induced sCADR.

Zhang X, Ma H, Hu C, Yu B, Ma W, Wu Z, Luo X, Zou H, Guan M.

Clin Chem Lab Med. 2015 Feb;53(3):383-90. doi: 10.1515/cclm-2014-0251.

PMID:
25257159
9.

Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea.

Park DJ, Kang JH, Lee JW, Lee KE, Wen L, Kim TJ, Park YW, Park SH, Lee SS.

Arthritis Care Res (Hoboken). 2015 Feb;67(2):280-7. doi: 10.1002/acr.22409.

10.

Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B*58:01.

Yun J, Marcaida MJ, Eriksson KK, Jamin H, Fontana S, Pichler WJ, Yerly D.

J Immunol. 2014 Apr 1;192(7):2984-93. doi: 10.4049/jimmunol.1302306. Epub 2014 Mar 3.

11.

HLA-B*58:01 strongly associates with allopurinol-induced adverse drug reactions in a Japanese sample population.

Niihara H, Kaneko S, Ito T, Sugamori T, Takahashi N, Kohno K, Morita E.

J Dermatol Sci. 2013 Aug;71(2):150-2. doi: 10.1016/j.jdermsci.2013.04.013. Epub 2013 Apr 19. No abstract available.

PMID:
23669020
12.

The p-i Concept: Pharmacological Interaction of Drugs With Immune Receptors.

Pichler WJ.

World Allergy Organ J. 2008 Jun;1(6):96-102. doi: 10.1097/WOX.0b013e3181778282.

13.

Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.

Hershfield MS, Callaghan JT, Tassaneeyakul W, Mushiroda T, Thorn CF, Klein TE, Lee MT.

Clin Pharmacol Ther. 2013 Feb;93(2):153-8. doi: 10.1038/clpt.2012.209. Epub 2012 Oct 17.

14.

2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.

Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Lioté F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R; American College of Rheumatology.

Arthritis Care Res (Hoboken). 2012 Oct;64(10):1431-46. doi: 10.1002/acr.21772. No abstract available.

15.

Human leukocyte antigens (HLA) associated drug hypersensitivity: consequences of drug binding to HLA.

Yun J, Adam J, Yerly D, Pichler WJ.

Allergy. 2012 Nov;67(11):1338-46. doi: 10.1111/all.12008. Epub 2012 Sep 3. Review.

16.

HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese.

Cao ZH, Wei ZY, Zhu QY, Zhang JY, Yang L, Qin SY, Shao LY, Zhang YT, Xuan JK, Li QL, Xu JH, Xu F, Ma L, Huang HY, Xing QH, Luo XQ.

Pharmacogenomics. 2012 Jul;13(10):1193-201. doi: 10.2217/pgs.12.89.

PMID:
22909208
17.

Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.

Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J, Frampton C, Dalbeth N.

Arthritis Rheum. 2012 Aug;64(8):2529-36. doi: 10.1002/art.34488.

18.

Allopurinol pharmacogenetics: assessment of potential clinical usefulness.

Zineh I, Mummaneni P, Lyndly J, Amur S, La Grenade LA, Chang SH, Rogers H, Pacanowski MA.

Pharmacogenomics. 2011 Dec;12(12):1741-9. doi: 10.2217/pgs.11.131.

PMID:
22118056
19.

Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe.

Génin E, Schumacher M, Roujeau JC, Naldi L, Liss Y, Kazma R, Sekula P, Hovnanian A, Mockenhaupt M.

Orphanet J Rare Dis. 2011 Jul 29;6:52. doi: 10.1186/1750-1172-6-52.

20.

Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans.

Kang HR, Jee YK, Kim YS, Lee CH, Jung JW, Kim SH, Park HW, Chang YS, Jang IJ, Cho SH, Min KU, Kim SH, Lee KW; Adverse Drug Reaction Research Group in Korea.

Pharmacogenet Genomics. 2011 May;21(5):303-7. doi: 10.1097/FPC.0b013e32834282b8. Erratum in: Pharmacogenet Genomics. 2012 Aug;22(8):652.

PMID:
21301380
Items per page

Supplemental Content

Write to the Help Desk